NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034
This study is recruiting at 21 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Neurocrine Biosciences
- Last updated on ClinicalTrials.gov
- March 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 2
- Neurocrine Clinical Site · Bryant, AR
- Neurocrine Clinical Site · Little Rock, AR
California · 5
- Neurocrine Clinical Site · Anaheim, CA
- Neurocrine Clinical Site · Pico Rivera, CA
- Neurocrine Clinical Site · San Diego, CA
- Neurocrine Clinical Site · Sherman Oaks, CA
- Neurocrine Clinical Site · Torrance, CA
Florida · 2
- Neurocrine Clinical Site · Hollywood, FL
- Neurocrine Clinical Site · Miami Lakes, FL
Georgia · 3
- Neurocrine Clinical Site · Atlanta, GA
- Neurocrine Clinical Site · Decatur, GA
- Neurocrine Clinical Site · Snellville, GA
Illinois · 1
- Neurocrine Clinical Site · Chicago, IL
Maryland · 1
- Neurocrine Clinical Site · Gaithersburg, MD
Massachusetts · 1
- Neurocrine Clinical Site · Watertown, MA
New Jersey · 1
- Neurocrine Clinical Site · Marlton, NJ
New York · 2
- Neurocrine Clinical Site · Staten Island, NY
- Neurocrine Clinical Site · The Bronx, NY
Texas · 3
- Neurocrine Clinical Site · Austin, TX
- Neurocrine Clinical Site · DeSoto, TX
- Neurocrine Clinical Site · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.